Key contributors include urbanization, an aging population, decreasing levels of physical activity, and increased levels of overweight and obesity
Most people may start noticing visible improvements in skin tone and clarity after 4 to 12 weeks of consistent use
Tirzepatide offers dual agonist activity, targeting both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, which may contribute to its enhanced weight loss efficacy compared to single-receptor agonists
Caroline Apovian, an obesity medicine specialist Massachusetts was among just 13 states whose Medicaid programs covered GLP-1s for weight loss at the beginning of 2026, according to the research organization KFF
Loss of the zinc receptor ZnR/GPR39 in mice enhances anxiety-related behavior and motor deficits, and modulates KCC2 expression in the amygdala